Legend Biotech Company (LEGN) Q1 2026 Earnings Name Could 12, 2026 8:00 AM EDT
Firm Individuals
Jessie Yeung – Vice President of Finance, Investor & Public Relations
Ying Huang – CEO & Director
Alan Bash – President of CARVYKTI®
Carlos Santos – Chief Monetary Officer
Guowei Fang – President of Analysis & Growth
Convention Name Individuals
Terence Flynn – Morgan Stanley, Analysis Division
Umer Raffat – Evercore ISI Institutional Equities, Analysis Division
Jessica Fye – JPMorgan Chase & Co, Analysis Division
Konstantinos Biliouris – Oppenheimer & Co. Inc., Analysis Division
Etzer Darout – Barclays Financial institution PLC, Analysis Division
Eric Schmidt – Cantor Fitzgerald & Co., Analysis Division
James Shin – Deutsche Financial institution AG, Analysis Division
Leonid Timashev – RBC Capital Markets, Analysis Division
Sean McCutcheon – Raymond James & Associates, Inc., Analysis Division
Ashwani Verma – UBS Funding Financial institution, Analysis Division
Yaron Werber – TD Cowen, Analysis Division
Presentation
Operator
Good day, and thanks for standing by. Welcome to the Legend Biotech First Quarter 2026 Earnings Convention Name.
[Operator Instructions] As we speak’s convention is being recorded. I’ll now hand the convention over to your speaker host for right this moment, Jessie Yeung, Vice President of Investor Relations and Finance. Please go forward. Good morning.
Jessie Yeung
Vice President of Finance, Investor & Public Relations
That is Jessie Yeung, Vice President of Investor Relations and Finance at Legend Biotech. Thanks for becoming a member of our convention name right this moment to overview our first quarter of 2026 efficiency.
Previous to this name, we issued a press launch asserting our monetary outcomes for the quarter. You will discover the press launch on our IR web site at legendbiotech.com. Becoming a member of me on right this moment’s name are Ying Huang, the corporate’s Chief Government Officer; Alan Bash, the corporate’s President of CARVYKTI; and Carlos Santos, the corporate’s Chief Monetary Officer. Following the ready remarks, we are going to open up the decision for Q&A. We even have our President of R&D, Guowei Fang, becoming a member of the Q&A session.
